Japan okays GSK’s Sotrovimab for treating Covid-19 patients

<p>
Japan has approved GlaxoSmithKline and Vir Biotechnology's Sotrovimab medicine as an antibody treatment for coronavirus, Health Minister Norihisa Tamura said on Monday.</p>
<p>
The antibody treatment is for mild to moderate COVID-19 cases which do not require oxygen supplementation, GSK said when it applied for fast-track approval this month.</p>
<p>
Sotrovimab has already been granted an emergency use approval by the FDA to facilitate the availability and use of this investigational monoclonal antibody for the treatment of COVID-19 in the U.S.</p>
<p>
GSK had claimed interim study results demonstrated an 85% reduction in hospitalisation for more than 24 hours or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial</p>